An observational study in Postpartum Hemorrhage Prevention by Using Oxytocin Verses Misoprostol, sponsored by Rasha Mohammed Mohammed Badawi. Status unknown at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-05.
Sponsored by Rasha Mohammed Mohammed Badawi · Observational
Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor
Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor as The data from a pharmacokinetics study suggested that the bioavaiblitiy of misoprostol after sub-lingual administration was higher than those after oral or vaginal administration
445 studies on the registry are indexed under Postpartum Hemorrhage; 75 are open to participants now.
This study's planned enrollment of 180 is above the median of 150 across 91 observational studies indexed under Postpartum Hemorrhage.
Browse Postpartum Hemorrhage studies →This is the only study on the registry with Rasha Mohammed Mohammed Badawi as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study will include (180)randomly allocated
Exclusion Criteria:
receive 400 Mg sublingual misoprostol.
receive 600 Mg sublingual misoprostol.
receive 5IU of intravenous oxytocin.
reduce blood loss during third and fourth stages of labor.
reduce blood loss during third and fourth stages of labor by using misopristol is better than using oxytocin
Time frame: 1 year
the duration of the third stage of labor ,need for oxytocics ,blood transfusion and any adverse effects of the drugs
the duration of the third stage of labor ,needed for oxytocics ,blood transfusion and any adverse effects of the drug will be reduced with mesopristol
Time frame: 1 year
This study is status unknown, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.